Generic placeholder image

Current Stem Cell Research & Therapy

Author(s): Grecia A. Cardoso-Hernández, Ana L. Camacho-Torres, Beni Camacho-Pérez, Fabio A. González Sánchez, José Navarro-Partida, Rebeca García-Varela, Jesús Aguilar-Aguilar and Juan P. Aguilar Alemán*

DOI: 10.2174/1574888X17666220829123908

DownloadDownload PDF Flyer Cite As
Mesenchymal Stem Cells: Case Report of an Adjuvant Ambulatory Therapy for a COVID-19 High-Risk and Steroid-hypersensitive Patients

Page: [1016 - 1025] Pages: 10

  • * (Excluding Mailing and Handling)

Abstract

Introduction: Due to the rapid progression of COVID-19 to severe and critical stages, thousands of patients have required the use of intensive care unit (ICU) treatment, placing an excessive strain on health systems. Immunomodulatory effects of Wharton’s Jelly Mesenchymal Stem Cells (WJ-MSCs) have shown promising results in the treatment of patients with COVID-19. However, the effect of promptly applied cell therapy on ambulatory patient prognosis has not been described. This case report presents the clinical outcome of a multimorbid, steroid-hypersensitive, COVID-19 patient treated with WJ-MSCs transplantation.

Case presentation: A 67-year-old woman with Type 2 diabetes, overweight (82 kg, 168 cm, BMI = 29.053), hypertension (190/60 mmHg) and steroid-hypersensitivity, tested positive for COVID-19 after presenting typical symptoms such as fatigue, chest pain, myalgia, nasal congestion, dysgeusia, anosmia and oxygen saturation (SpO2) 94% - 96%, with normal body temperature (36°C). The patient received pharmacologic treatment but, when symptoms worsened, WJ-MSCs were transplanted to modulate the suspected onset of the cytokine release syndrome. Significant improvement of symptoms and clinical parameters (inflammatory markers and CT score) was observed, and the patient fully recovered within a short period of time.

Conclusion: The present case report exhibits the favorable outcome of using Wharton’s Jelly Mesenchymal Stem Cells (WJ-MSCs) as an ambulatory and adjuvant therapy for COVID-19. Prompt WJ-MSCs infusion can be a safe ambulatory adjuvant therapy in COVID-19 infection care, preventing disease progression to critical stages and avoiding hospital overcrowding.

Keywords: Cellular therapy, Clinical translation, Immunotherapy, Mesenchymal stem cells (MSCs)

Graphical Abstract

[1]
Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: Properties and clinical application. Stem Cells Int 2018; 2018: 3057624.
[http://dx.doi.org/10.1155/2018/3057624] [PMID: 30013600]
[2]
El Omar R, Beroud J, Stoltz JF, Menu P, Velot E, Decot V. Umbilical cord mesenchymal stem cells: The new gold standard for mesenchymal stem cell-based therapies? Tissue Eng Part B Rev 2014; 20(5): 523-44.
[http://dx.doi.org/10.1089/ten.teb.2013.0664] [PMID: 24552279]
[3]
Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: Present or future. Stem Cell Rev Rep 2020; 16(3): 427-33.
[http://dx.doi.org/10.1007/s12015-020-09973-w] [PMID: 32281052]
[4]
Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med 2021; 10(5): 660-73.
[http://dx.doi.org/10.1002/sctm.20-0472] [PMID: 33400390]
[5]
Zhang Y, Ding J, Ren S, et al. Intravenous infusion of human umbilical cord Whar-ton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther 2020; 11(1): 207.
[6]
Mexico. Secretaria de Salud. Coronavirus COVID 19. 2021 Historical Daily Technical Releases. 2021. Available from: https://www.gob.mx/salud/acciones-y-programas/coronavirus-covid19-comunicados-tecnicos-diarios-historicos-2021 (Accesed on: February 23, 2021).
[7]
Pu J, Leader JK, Bandos A, et al. Automated quantification of COVID-19 severity and progression using chest CT images. Eur Radiol 2021; 31(1): 436-46.
[http://dx.doi.org/10.1007/s00330-020-07156-2] [PMID: 32789756]
[8]
Sales AR, Casagrande EM, Hochhegger B, Zanetti G, Marchiori E. The reversed halo sign and COVID-19: Possible histopathological mechanisms related to the appearance of this imaging finding. Arch Bronconeumol 2021; 57: 73-5.
[http://dx.doi.org/10.1016/j.arbres.2020.06.029] [PMID: 34629671]
[9]
Lei Q, Li G, Ma X, et al. Correlation between CT findings and outcomes in 46 patients with coronavirus disease 2019. Sci Rep 2021; 11(1): 1103.
[http://dx.doi.org/10.1038/s41598-020-79183-4]
[10]
Pan Y, Guan H. Imaging changes in patients with 2019-nCov. Eur Radiol 2020; 30(7): 3612-3.
[http://dx.doi.org/10.1007/s00330-020-06713-z] [PMID: 32025790]
[11]
Canham MA, Campbell JDM, Mountford JC. The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019. J Transl Med 2020; 18(1): 359.
[http://dx.doi.org/10.1186/s12967-020-02532-4] [PMID: 32958009]
[12]
Cen Y, Chen X, Shen Y, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019— A multi-centre observational study. Clin Microbiol Infect 2020; 26(9): 1242-7.
[http://dx.doi.org/10.1016/j.cmi.2020.05.041] [PMID: 32526275]
[13]
Feng Z, Yu Q, Yao S, et al. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun 2020; 11(1): 4968.
[http://dx.doi.org/10.1038/s41467-020-18786-x] [PMID: 33009413]
[14]
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020; 368: m1091. Available from: https://www.bmj.com/content/368/bmj.m1091/
[15]
Zantah M, Dominguez Castillo E, Townsend R, Dikengil F, Criner GJ. Pneumothorax in COVID-19 disease- incidence and clinical characteristics. Respir Res 2020; 21(1): 236.
[http://dx.doi.org/10.1186/s12931-020-01504-y] [PMID: 32938445]
[16]
Biamonte F, Botta C, Mazzitelli M, et al. Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility. J Transl Med 2021; 19(1): 79.
[http://dx.doi.org/10.1186/s12967-021-02744-2] [PMID: 33596963]
[17]
Ali N. Elevated level of C‐reactive protein may be an early marker to predict risk for severity of COVID‐19. J Med Virol 2020; 92(11): 2409-11.
[http://dx.doi.org/10.1002/jmv.26097] [PMID: 32516845]
[18]
Cheng L, Li H, Li L, et al. Ferritin in the Coronavirus Disease 2019 (COVID‐19): A systematic review and meta‐analysis. J Clin Lab Anal 2020; 34(10): e23618.
[http://dx.doi.org/10.1002/jcla.23618]
[19]
Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem or stromal cells: A review of clinical applications and manufacturing practices. Transfusion 2014; 54(5): 1418-37.
[http://dx.doi.org/10.1111/trf.12421] [PMID: 24898458]
[20]
Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol 2018; 9: 754.
[http://dx.doi.org/10.3389/fimmu.2018.00754] [PMID: 29706967]
[21]
Devaraj S, Jialal I. C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol 2011; 31: 1397-402.
[http://dx.doi.org/10.1161/ATVBAHA.111.225508]
[22]
Shao M, Xu Q, Wu Z, et al. Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p. Stem Cell Res Ther 2020; 11(1): 37.
[http://dx.doi.org/10.1186/s13287-020-1550-0] [PMID: 31973730]
[23]
Sonnweber T, Boehm A, Sahanic S, et al. Persisting alterations of iron homeostasis in COVID-19 are associated with non-resolving lung pathologies and poor patients’ performance: A prospective observational cohort study. Respir Res 2020; 21(1): 276.
[http://dx.doi.org/10.1186/s12931-020-01546-2] [PMID: 33087116]
[24]
Jacob G, Aharon A, Brenner B. COVID-19-Associated hyper-fibrinolysis: Mechanism and implementations. Front Physiol 2020; 11: 596057.
[http://dx.doi.org/10.3389/fphys.2020.596057] [PMID: 33391014]
[25]
Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020; 18(1): 206.
[http://dx.doi.org/10.1186/s12967-020-02374-0] [PMID: 32434518]
[26]
Lee KS, Han J, Chung MP, Jeong YJ. Radiology Illustrated Chest Radiology. Berlin, Heidelberg: Springer Verlag 2014.
[http://dx.doi.org/10.1007/978-3-642-37096-0]
[27]
Iglesias M, Butrón P, Torre-Villalvazo I, et al. Mesenchymal stem cells for the compassionate treatment of severe acute respiratory distress syndrome due to COVID 19. Aging Dis 2021; 12(2): 360-70.
[http://dx.doi.org/10.14336/AD.2020.1218] [PMID: 33815870]
[28]
Saleh M, Vaezi AA, Aliannejad R, et al. Cell therapy in patients with COVID-19 using wharton’s jelly mesenchymal stem cells: A phase 1 clinical trial. Stem Cell Res Ther 2021; 12(1): 410.
[http://dx.doi.org/10.1186/s13287-021-02483-7] [PMID: 34271988]
[29]
U.S. – NIH. Database of privately and publicly funded clinical studies conducted around the world. Available from: https://www.clinicaltrials.gov/
[30]
FDA Important patient and consumer information about regenerative medicine therapies. 2021. Available from: [https://www.fda. gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
[31]
Nekanti U, Mohanty L, Venugopal P, Balasubramanian S, Totey S, Ta M. Optimization and scale-up of wharton’s jelly-derived mesenchymal stem cells for clinical applications. Stem Cell Res 2010; 5(3): 244-54.
[http://dx.doi.org/10.1016/j.scr.2010.08.005] [PMID: 20880767]
[32]
Wu M, Yao L, Wang Y, et al. Clinical evaluation of potential usefulness of serum Lactate Dehydrogenase (LDH) in 2019 novel Coronavirus (COVID-19) pneumonia. Respir Res 2020; 21(1): 171.
[http://dx.doi.org/10.1186/s12931-020-01427-8] [PMID: 32631317]